Can an existing vaccine be used to control a coronavirus pandemic?

2020 May 14 News /BioValleyBIOON / - Researchers around the world are competing to develop a vaccine to protect us from deadly infectious diseases the attack, which is a raceThe candidate vaccine is currently investigating as many as 115 kinds of impressive, but to make a vaccine approval will take several monthsresearchers have more than 25 different viruses and bacteria that infect humansdeveloped hundreds of vaccineWe can protect themselves from cholera infection from rabies virusAll the common goal of vaccines is to induce an immune response to prevent future diseaseIs it possible one of these existing vaccines can also induce protection against SARS-CoV-2 - the virus that leads to COVID-19?Source: https://cn.bing.com reuse pharmaceutical treatment COVID many popular strategy test -19, for example Ebola or Western Wei antimalarial drugs Reid hydroxychloroquine performedIf approved vaccine can lessen the severity of COVID-19, which would be a really good newsas a BCG vaccine may help control COVID-19 is widely used, recently received attentionFew studies have found that in a country COVID-19 severity and the number of people vaccinated there is an interesting correlation between BCGBCG significantly reduces the damage caused COVID-19What is BCG? In the past century, the vaccine protects against tuberculosis infection of millions of people The vaccine is made in France AlbertCalmette and CamilleGuerin development, they used bacteria called Mycobacterium bovis, which weaken attenuated, and name it BacilleCalmetteGuerin, hence the name BCG M bovis is the cause of bovine tuberculosis This is a disaster, leading to a year in the UK thousands of cattle were killed BCG is a good example of how harmful animal pathogens is how it is used for the benefit of mankind However, bacteria cattle and the human body is clearly SARS-CoV-2 virus is very different, therefore, a significant benefit of BCG vaccine is thought to be due to its ability to enhance the ability of the immune system BCG against those who claim to have a positive effect on reducing the severity of COVID-19 of the article, there are an equal number of negative reports these findings Obviously, there are many in the initial study untenable assumptions; we know that vaccination rates are often inaccurate, calculated on mortality countries different methods There are a large number of confounding factors that impede reasonable to conclude, such as population density, and the average age of SARS-CoV-2 detection rate a vaccination in all countries vaccines often quite similar It was suggested that associated with BCG COVID-19 and another intermediary actually reflects the protective effect of the vaccine MMR University of Cambridge scientists believe a vaccine, measles, mumps and rubella (MMR) vaccine It may help drive a protective immune response to SARS-CoV-2's MMR vaccine is generally used for large 9-month baby, so this assumption and children COVID-19 has significant observations resistance is very consistent measles, critical analysis of protein structure mumps and rubella virus showed some unexpected thereof with certain proteins similar to SARS-CoV-2 sex In particular, SARS-CoV-2 of the "spike protein" measles "fusion protein" 20% of similarities It is not clear whether this is sufficient to elicit cross-reactive immune response, but this may be the focus of future research Ultimately, the need for detailed study in a large population to determine previous BCG vaccination, MMR or other vaccines if you can reduce the severity of COVID-19's Before COVID-19-specific vaccines have been licensed, it can be concluded that these studies? The game will continue, let us wait and see (Biovalley Bioon.com) References: [1] Couldthecoronaviruspandemicbecontrolledusingexistingvaccines ? [2] TheCOVID-19vaccinedevelopmentlandscape [3] CorrelationbetweenuniversalBCGvaccinationpolicyandreducedmorbidityandmortalityforCOVID -19: anepidemiologicalstudy [4] AssociationBetweenBCGPolicyisSignificantlyConfoundedbyAgeandisUnlikelytoAlterInfectionorMortalityRates [5]


EarlypeekatdataonGileadcoronavirusdrugsuggestspatientsarerespondingtotreatment [6] HomologousproteindomainsinSARS-CoV-2andmeasles, mumpsandrubellaviruses: preliminaryevidencethatMMRvaccinemightprovideprotectionagainstCOVID-19